Synthetic-rating coverage uses the latest fiscal year's EBIT over the SAME year's interest expense (no trailing-twelve-month interest could be formed from the quarterly tagging) — a matched-window ratio, never TTM earnings over annual interest.
No four consecutive quarters could be summed for EPS (Diluted), Interest Expense; these figures use the latest fiscal year, not a trailing twelve months.
full derived coverage requires a plan
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
— Months · distinct values (the real sample size).
Metric
Today
Own median
Own range
%ile
z
Sector med.
mo · distinct
P/E
1942.89×
only 7 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
7.5%
−22.3%
no band (55 mo · 5 distinct)
—
—
−36.9%
55 · 5
24.1%
−116.7%
no band (43 mo · 4 distinct)
—
—
−15.4%
43 · 4
5.4%
−123.9%
95th
+0.85σ
−21.3%
67 · 6
12M Momentum
5.4%
only 10 monthly observations — under the 12-month floor for a series line.
EPS Growth 3Y
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
55.7%
—
no band (31 mo · 3 distinct)
—
—
9.0%
31 · 3
Market Cap
$545.65B
not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.
ROE (point-in-time)Health Care median, same monthshaded = own p10–p90 · dashed = own median · right-edge tick = today
shown for reference only — the reconstructed distribution did not clear the band gate, so no rank is quoted.
Multiple-implied price ladder · Full
Filed earnings only.
no P/E ladder — only 7 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Ladder not drawn for this name — the reason is above.ⓘ
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Percentile through time (point-in-time cohort)
Loading the monthly cohort placement…
▸Comp setname your own peers — pick a pool or add tickers
Covered pool$977.78B +7.6%/yr 2020→2025Concentration484 of 10,000fragmented · top 3 hold 22.9% · −24 pts since 2020ONC0.5% · rank 23 of 348 · +0.5pp over 5y· CV 0.64 · σ 0.2pp
Who holds the poolCY2025 · bars scaled to the largest member
Growth, restated as sharewhere each pace has to END UP, by 2030
Its own realised pace0.5% → 3.5%
The pace the price requires— The growth today's price requires (our reverse-DCF) is a Pro metric — the realized-pace runway above is free.
ONC share over time6 published years
Calendar year
2020
2021
2022
2023
2024
2025
Share of covered pool
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
coverage: 321 of the 385 members that…
Share of covered industry revenue · n=348 in Pharmaceuticals & Biotechnology · CY2025 pool · built 2026-08-19 not market shareⓘ
Covered filers only, not market share — private and uncovered companies are missing, so every share here reads high. Years are FX-converted and published only once most of the pool has filed.
